SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- diabetes

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dr.praveen who wrote (215)12/6/2007 11:04:10 AM
From: tuck   of 278
 
[PPAR-gamma regulates osteoclastogenesis in mice: glitazones cause osteoporosis in mice & might in humans]

(wherever you see "PPAR-" here, assume it is "PPAR-gamma")

>>Nature Medicine
Published online: 2 December 2007 | doi:10.1038/nm1672

PPAR- regulates osteoclastogenesis in mice

Yihong Wan1, Ling-Wa Chong1 & Ronald M Evans1

Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of the monocyte-macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis1. Although peroxisome proliferator–activated receptor- (PPAR-) has been shown to inhibit osteoblast differentiation2, 3, its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR- agonists, "such as thiazolidinediones—" a class of insulin-sensitizing drugs, have been reported to cause a higher rate of fractures in human patients4, 5. Here we have uncovered a pro-osteoclastogenic effect of PPAR- by using a Tie2Cre/flox mouse model in which PPAR- is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor-B ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR- by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Our examination of the underlying mechanisms suggested that PPAR- functions as a direct regulator of c-fos expression, an essential mediator of osteoclastogenesis6. Therefore, PPAR- and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.

1 Howard Hughes Medical Institute, Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California 92037, USA.<<

PPAR work is notoriously tricky, and this may not translate to humans, but there have been reports of bone fractures in human patients.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext